Neurotech Insights
December 31, 2007
Inside This Issue: Migraine
Events: Neuromodulation Society Conference Highlights
Top News Alerts: Product Updates, Deals and Financings
Featured Company: TorreyPines: Refocusing Pipeline on Women's Health
Subscribe now to access over hundreds of articles covering developments in drugs, devices and diagnostics for the brain and nervous system.
Market Highlights: FDA Adds New Roadblocks to Indiplon Approval
Neurocrine (NBIX) executives and analysts alike were shocked mid-month when the FDA handed the company another approvable letter with a completely new set of terms for approval of its insomnia drug indiplon. The letter requests three new studies, not mentioned in the previous letter, including a clinical study in elderly patients, a preclinical pregnancy study, and a clinical safety study comparing indiplon to an already approved insomnia drug. Prana (PRAN) was up 86% as investors anticipate positive results from their Phase IIa of PBT2 in Alzheimer’s in the beginning of 2008 (see story, page 5). Neurochem (NRCM) was down 31% after the EMEA refused to approve their lead drug, Kiacta for AA amyloidosis...
Therapeutic Approaches to Migraine
Migraines are unilateral headaches associated with nausea, vomiting or sensitivity to light (photophobia), sounds (phonophobia), or smells. The headaches are typically throbbing or pulsing and of moderate to severe intensity. They tend to last anywhere from four hours to three days and become worse with exertion. Approximately one third of patients have a preceding sensory experience, called an aura. Migraine treatment includes three components. One is prophylactic and aims to prevent attacks from occurring. The second is abortive and aims to stop the attack, while the third is analgesic and is aimed at making the patient more comfortable...
TorreyPines: Refocusing Pipeline on Women's Health
TorreyPines Therapeutics (TPTX) has its origins in 2000, when Boston based investor Advent International decided to start a company with Harvard Professor Rudolph Tanzi to develop new therapies for Alzheimer's disease (AD). The company, Neurogenetics, was located in La Jolla, California to take advantage of hiring a group of experienced Alzheimer’s researchers who left Sibia Neuroscience when it was acquired by Merck at the end of 1999. In 2002, Dr. Neil Kurtz, a veteran with a fifteen year background in big pharma, became the CEO of the company. We talked to him about TorreyPines and its new pain drug tezampanel...
Companies Covered In This Issue Include: 7TM Pharma, Amarin, Adolor, Biogen Idec, Ceregene, Jazz Pharmaceuticals,Transition Therapeutics, Pfizer, Boston Scientific, Merck, CoMentis, Neurochem, Neurocrine, Medtronic, UCB, Prana, Nabi, Eisai, BioArctic, GlaxoSmithKline, Epix Pharmaceuticals, Shering Plough, Cyberonics, Northstar Neuroscience, Alfred Mann Foundation, AstraZeneca, Actelion, Intra-Cellular Therapies, Elan, Wyeth, Cognition Therapeutics, G-Nostics, Whatman, Addex Pharmaceuticals, Axogen, Neurobiological Technologies, Axogen, NeuroVasx, Acura Pharmaceuticals, King Pharmaceuticals, Mylan, NeuroHealing, Ambrx, Eli Lilly, Arcion Therapeutics,Fovea Pharmaceuticals, BioMS Pharmaceuticals, Posit Science, Scientific Learning, Lineagen, Theraquest, Neurotrax, NeuroMetrix, EyeTel, Alexza, Endo Pharmaceuticals, Somaxon, Solstice Neuroscience, Valeant, Map Pharmaceuticals, D-Pharm, NuPathe, Novadel, Pozen, Neuralieve, Novadel, ProEthic
Subscribe Now:
|
|
